Modulated RF Hyperthermia – 13.56 MHz mHT Technology

Modulated RF-hyperthermia (mHT) is an advanced heating therapy that uses synergized thermal and nonthermal (electromagnetic) effects to heat and destroy malignant cells in a SELECTIVE manner, without damaging healthy cells.

mHT is the latest generation medical innovation that delivers selective, controlled, and deep energy (hyperthermic + electromagnetic) using capacitively coupled 13.56 MHz amplitude modulated radiofrequency to cancer cells.

Superior Deep Action in Oncology

13.56 MHz mHT with 2 electrodes can penetrate up to 38.4 cm in depth and has been shown superior to 8 MHz cCHT
(Reference).

mHT delivers thermal energy only to the tumor cell membrane and extracellular matrix, using temperatures below 43 °C, addressing the limitations of traditional hyperthermia at a near cellular level.

Selective targeting mechanism of modulated RF hyperthermia mHT on cancer cells
Fig. 1. Selective mechanism of mHT. Modulated radiofrequency current flows primarily into the extracellular electrolyte because normal cells are electronically isolated by more than one million V/m electric field strength (Hegyi G, Szasz O, Szasz A. PMID: 24494322.)

The Clinical Benefits of Amplitude Modulated RF Hyperthermia

Chemotherapy & Biological Support

Better perfusion: Due to the vasodilation effect, mHT ensures better delivery of chemotherapeutic or biological substances (ref), improving treatment outcomes.

Radio Sensitization

Changes in oxygenation of tumor and adjacent tissue make mHT an excellent choice before and after radiotherapy, sensitizing the tumor for enhanced radiation efficacy (ref).

Immunogenic Effects (Abscopal)

ICD Inducer: mHT modulates the Tumor Micro Environment (TME), triggering DAMP and HSP70. This activates NK cells and matures Dendritic Cells (DC), creating a systemic response on distant metastases.

mHT (ICD inducer) -> DAMP -> HSP70 -> DC -> T-cells (CTL, Th1, Tmemory) -> Systemic Antitumor Response

Shown superior to nivolumab and ipilimumab in GI cancers by Ralph Kleef et. all
(ref).

Clinical Outcomes: Overall Survival (OS) & QoL

Increased Overall Survival (OS) in cancer has been clinically shown multiple times with the addition of mHT, in addition to local tumor control and increased Quality of Life (QoL) (ref).

Supporting adjuvant, neoadjuvant, and palliative therapy for neoplastic pathologies, infections, inflammation, and pain.

Advanced mHT: Andromedic’s HyDeep 600WM

The Andromedic modulated hyperthermia device utilizes 13.56 MHz as carrier RF and combines it with Radio Frequencies Specific for Each Pathology and Cancer Type, significantly improving the outcomes of classical mHT.


Explore HyDeep 600WM Device Technology